June 12, 2021 15:11 UTC
DNMR CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Danimer Scientific, Inc.
DNMR CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Danimer Scientific, Inc. June 12, 2021 15:11 UTC DNMR CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Danimer Scientific, Inc. RADNOR, Pa.--(BUSINESS WIRE)-- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer”) f/k/a Live Oak Acquisition Corp. (NYSE: LOAK) (“Live Oak”) on behalf of those who purchased or acquired Danimer securities betwe
June 12, 2021 21:01 UTC
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference June 12, 2021 21:01 UTC Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference -- First presentation of long-term safety and disease control data from Phase 3 TRuE-AD studies of ruxolitinib cream in atopic dermatitis WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatiti
June 12, 2021 14:00 UTC
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis June 12, 2021 14:00 UTC Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis -- 94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial -- -- Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort -- -- Late-breaking Data Presented at European Hematology Association (EHA)
June 11, 2021 19:04 UTC
CORRECTING and REPLACING – Domo Joins Snowflake’s Snowpark Accelerated Program
CORRECTING and REPLACING – Domo Joins Snowflake’s Snowpark Accelerated Program June 11, 2021 19:04 UTC CORRECTING and REPLACING – Domo Joins Snowflake’s Snowpark Accelerated Program Domo Announces New Integration to Snowpark to Make it Easier for Developers, Data Engineers and Data Scientists to Build and Extend Custom Data-Driven Solutions Across the Enterprise CORRECTION...by DomoSILICON SLOPES, Utah--(BUSINESS WIRE)-- Please replace the release dated June 10, 2021 with the following corrected version. In the fourth paragraph of the release, the quote attribution has been updated. The updated release reads: DOMO JOINS SNOWFLAKE’S SNOWPARK ACCELERATED PROGRAM Domo
June 11, 2021 05:00 UTC
ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity
ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity June 11, 2021 05:00 UTC ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity Ipsen analyzed data held in two large U.S. medical insurance databases, amounting to over 15 million patients, including nearly 1.3 million people living with active spasticity1 Despite being a recommended first-line treatment, only 3-4% of eligible adults living with active spasticity were treated with botulinum neurotoxin type A (BoNT-A)1 These data comprise one of 13 abstracts that Ipsen is presenting at the virtual ISPRM 2021 Congress PARIS--(BUSINESS WIR
June 11, 2021 04:02 UTC
FREYR in Negotiations for Building Battery Production Facilities in the United States
FREYR in Negotiations for Building Battery Production Facilities in the United States June 11, 2021 04:02 UTC FREYR in Negotiations for Building Battery Production Facilities in the United States OSLO, Norway & NEW YORK--(BUSINESS WIRE)-- FREYR AS (FREYR), the Norway-based developer of clean, next-generation battery cell production capacity, and Alussa Energy Acquisition Corp. (Alussa Energy), disclosed that FREYR is in negotiations with a major multinational industrial conglomerate (the JV Partner) to potentially develop battery production facilities in North America. This development was noted by FREYR Battery in its 9 June 2021 filing of a third amendment to the registration s

Execution time: 0.3496 seconds
Layout: desktop